PO.PS01.06 · 人群科学

Patterns of tobacco use, cessation interventions, and lung cancer screening in rural vs. urban areas over time; a 10-year retrospective cohort study

编号 5045 展板 18 时间 4/21 09:00–12:00 区域 Section 35 主讲 Brianna Tranby, MA
分会场 Diet, Alcohol, and Tobacco, and Other Lifestyle Factors
该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Brianna Tranby1, Paul A. Decker1, Jiang Ruoxiang1, David Midthun1, Lori C. Sakoda2, Melinda C. Aldrich3, Debra Friedman3, Adoma Manful3, Oindrila Bhattacharyya4, Christi Patten1, Chyke A. Doubeni4

1Mayo Clinic, Rochester, MN,2Kaiser Permanente, Oakland, CA,3Vanderbilt University Medical Center, Nashville, TN,4The Ohio State University Wexner Medical Center, Columbus, OH

摘要 Abstract

Introduction: Lung cancer rates differ across rural and urban areas, but few studies have evaluated rural-urban differences across the risk-screening continuum. We examined smoking, cessation interventions, and lung cancer screening patterns across the rural-urban continuum in a geographically defined area over 10 years. Materials and Methods: A retrospective cohort study (2014-2023) was conducted using clinical data from the Rochester Epidemiology Project, derived from healthcare encounters in a 27-county region of the midwestern United States. Patients ages 40-80 were included. We used Rural-Urban Commuting Area codes to assign residence as urban, rural, or highly rural. We examined yearly smoking prevalence, cessation intervention (pharmacotherapy, counseling), and low-dose computed tomography (LDCT) lung cancer screening. Results: Over the 10-year study period, the sample size ranged from 305,530 to 340,411 people annually with 36-38% urban, 56-57% rural, and 6-7% highly rural. Current smoking prevalence declined from 14 to 12% over the 10-year period (range=12-16%; p =0.06) and was consistently lower in urban areas (range=10-14%) than rural (range=12-17.0%) and highly rural areas (range=12-18%; p =<0.001). Among individuals who currently smoked with no history of lung cancer, yearly smoking cessation intervention ranged from 16% to 23%, increasing over the 10-year period ( p =<0.001). Cessation medication (varenicline, bupropion, or nicotine replacement) prescription consistently increased overall over time but remained higher in urban than rural and highly rural areas ( p =<0.001). Cessation counseling rates also increased overall over time and were similar between urban and rural areas and lower in highly rural areas ( p =<0.001). Among people who had ever-smoked aged 50-80 years with no diagnosis of lung cancer, LDCT screening increased from 0.0% to 3.1% over the study period. Increases were higher in urban areas (0.0-3.6%) and similar in rural and highly rural areas (0.0-2.8% and 0.0-2.9%, respectively; p =<0.001). Among people who currently smoked, LDCT screening also increased over the study period (0.0-6.4%), with higher increases in urban (0.1-8.0%) than rural (0.0-5.7%) or highly rural (0.1-6.1%) areas ( p =<0.001). After the new screening guidelines in 2021, rates in all areas increased year-on-year. Conclusion: In this cohort, we found that smoking prevalence, cessation interventions, and lung cancer screening improved from 2014-2023 across the rural-urban continuum. Unfortunately, smoking prevalence remained higher and cessation interventions and screening rates lower in rural compared to urban areas. The persistent patterns underscore the need for strategies to overcome barriers for rural residents and improve lung cancer prevention and early detection in all areas.
利益披露 Disclosure
B. Tranby, None.. P. A. Decker, None.. J. Ruoxiang, None.. D. Midthun, None. L. C. Sakoda, AstraZeneca ). M. C. Aldrich, None.. D. Friedman, None.. A. Manful, None.. O. Bhattacharyya, None.. C. Patten, None.. C. A. Doubeni, None.

在会议检索中打开